Arcus Biosciences (RCUS) Scheduled to Post Earnings on Monday

Arcus Biosciences (NYSE:RCUSGet Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, May 9th. Analysts expect the company to announce earnings of $0.83 per share for the quarter.

Arcus Biosciences (NYSE:RCUSGet Rating) last posted its quarterly earnings data on Wednesday, February 23rd. The company reported $3.71 EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $4.84. The business had revenue of $354.50 million for the quarter, compared to analyst estimates of $8.87 million. Arcus Biosciences had a return on equity of 7.96% and a net margin of 13.80%. On average, analysts expect Arcus Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcus Biosciences stock opened at $24.21 on Monday. Arcus Biosciences has a 52 week low of $22.36 and a 52 week high of $49.10. The firm has a market capitalization of $1.74 billion, a PE ratio of 56.30 and a beta of 0.85. The business’s 50-day simple moving average is $32.76 and its 200-day simple moving average is $35.69.

In other Arcus Biosciences news, COO Jennifer Jarrett sold 9,617 shares of the business’s stock in a transaction that occurred on Wednesday, March 16th. The stock was sold at an average price of $31.62, for a total value of $304,089.54. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 12.30% of the company’s stock.

Large investors have recently bought and sold shares of the business. Royal Bank of Canada boosted its holdings in shares of Arcus Biosciences by 217.2% during the 2nd quarter. Royal Bank of Canada now owns 3,102 shares of the company’s stock worth $85,000 after buying an additional 2,124 shares during the period. BNP Paribas Arbitrage SA raised its stake in Arcus Biosciences by 103.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 11,565 shares of the company’s stock worth $403,000 after purchasing an additional 5,879 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Arcus Biosciences in the 4th quarter worth about $705,000. UBS Group AG raised its stake in Arcus Biosciences by 196.7% in the 3rd quarter. UBS Group AG now owns 20,956 shares of the company’s stock worth $731,000 after purchasing an additional 13,894 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Arcus Biosciences in the 3rd quarter worth about $786,000. 73.54% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently issued reports on RCUS shares. SVB Leerink restated an “outperform” rating on shares of Arcus Biosciences in a research note on Friday, January 7th. The Goldman Sachs Group decreased their price objective on Arcus Biosciences from $45.00 to $43.00 in a report on Thursday, January 13th. Zacks Investment Research lowered Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, March 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research note on Friday, April 1st. Finally, Truist Financial lifted their price objective on Arcus Biosciences from $70.00 to $77.00 in a research report on Friday, February 25th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $64.43.

About Arcus Biosciences (Get Rating)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.

Further Reading

Earnings History for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.